The United Kingdom has a rich history of scientific discovery and innovation, and the life sciences industry is no exception. Over the years, this sector has undergone a remarkable evolution, transforming into a dynamic and globally influential hub for research, development, and commercialisation of therapies, diagnostics and devices. This change to the industry comes with its challenges, for scientists and the buildings they operate from.
(article continues below image)
Background
The roots of the UK's life sciences industry can be traced back centuries, with early breakthroughs in biology, medicine, and chemistry. Prominent figures like Charles Darwin, Alexander Fleming, and Rosalind Franklin made groundbreaking contributions that laid the foundation for modern life sciences research. These pioneers set the stage for the country's future leadership in the field.
The 1970s and 1980s witnessed the emergence of biotechnology as a driving force in the life sciences sector. UK-based companies like Genentech and Biogen played pivotal roles in advancing genetic engineering and the development of biopharmaceuticals. This period marked the beginning of the UK's reputation as a global biotech innovator.
The UK is also home to several pharmaceutical giants, such as GlaxoSmithKline (GSK) and AstraZeneca. These companies have played vital roles in drug discovery and development, producing life-changing medications and vaccines that have had a worldwide impact. GSK, for example, developed the first HIV/AIDS treatment, Acyclovir, in the 1980s. This was demonstrated again during the COVID-19 pandemic. The UK showcased its prowess in vaccine development and distribution, the rapid development and deployment of vaccines by AstraZeneca and collaboration with the University of Oxford were pivotal in the global fight against the virus. High throughput screening and genomic analysis saw the UK lead the tracking and tracing of viral mutations helping to ensure vaccines remained effective against novel strains.
The UK research sector continues to compete at the highest global level generating dozens of pioneering therapeutic, diagnostic and medical device technologies annually from its applied research. The UK is home to no less than four of the top ten Universities globally. As a result, the real estate market for life science has become an integral component of the country's economic landscape. However, this growth has not come without its fair share of challenges. Despite its impressive contribution to the global life science sector, UK development companies nor their real estate counterparts have been able to maintain the pace of activity in the United States. It is now recognized that there is a direct link between the built environment and the growth rate of life science sector.
Trilogy
Over the next three weeks, we will be releasing three articles that describes how the UK Life Sciences Industry has involved. The articles are written by Dr Neha Tanna - medical doctor and life science investor, Michael Cunniffe - Managing director of Danforth Advisors, who specialise in the life science industry - and Ryan Matenchuk - founder and CEO of Galileo Labs - a London-based start-up that operates lab space for life science scale-ups.
About the Authors
Dr Neha Tanna is a licensed medical doctor with many years of experience in the Biopharma industry. She works as part of senior leadership teams in the biotech industry and as a venture capital investor.
Michael Cunniffe is the Managing Director, UK of Danforth Advisors. Danforth provide development and corporate support functions on a fractional basis to high growth life science companies across all development stages, from seed to public, including IPO and fundraising transactions.
Ryan Matenchuk is a real estate finance professional with a depth of experience working in the property industry for over 20 years. He worked closely with the design and development teams, investors, vendors and debt providers to bring significant projects to life.
Comments